Seminars in Pediatric Neurology
Volume 18, Issue 4 , Pages 230-238, December 2011

Nemaline Myopathies

  • Carina Wallgren-Pettersson, MD

      Affiliations

    • The Folkhälsan Institute of Genetics and Department of Medical Genetics, Haartman Institute, University of Helsinki, Helsinki, Finland
    • Corresponding Author InformationAddress reprint requests to Carina Wallgren-Pettersson, MD, The Folkhälsan Institute of Genetics and Department of Medical Genetics, Haartman Institute, University of Helsinki, PO Box 211, 025 Helsinki, Finland
  • ,
  • Caroline A. Sewry, PhD

      Affiliations

    • Dubowitz Neuromuscular Centre, Institute of Child Health, London, UK
    • Wolfson Centre for Inherited Neuromuscular Diseases, RJAH Orthopaedic Hospital, Oswestry, UK
  • ,
  • Kristen J. Nowak, PhD

      Affiliations

    • Centre for Medical Research, University of Western Australia and Western Australian Institute for Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia
  • ,
  • Nigel G. Laing, PhD

      Affiliations

    • Centre for Medical Research, University of Western Australia and Western Australian Institute for Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia

Nemaline myopathy constitutes a continuous spectrum of primary skeletal muscle disorders named after the Greek word for thread, nema. The diagnosis is based on muscle weakness, combined with visualization of nemaline bodies on muscle biopsy. The patients' muscle weakness is usually generalized, but there may be a selective pattern of more pronounced weakness, and, most importantly, respiratory muscles may be especially weak. Histologically, additional features may coexist with the nemaline bodies. There are 7 known causative genes. The function of the most recently identified gene is unknown, but the other 6 encoded proteins are associated with the muscle thin filament. The 2 most common causes of nemaline myopathy are recessive mutations in nebulin and de novo dominant mutations in skeletal muscle α-actin. At least 1 further gene remains to be identified. Patient care is based on managing the clinical symptoms. Animal models are helping to gain insight into pathogenesis, and a variety of therapeutic approaches are being investigated.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 10.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1071-9091(11)00089-1

doi:10.1016/j.spen.2011.10.004

Seminars in Pediatric Neurology
Volume 18, Issue 4 , Pages 230-238, December 2011